CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia

G. D'Arena, P. Musto, N. Cascavilla, M. Dell'Olio, N. Di Renzo, G. Perla, L. Savino, M. Carotenuto

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

CD38 identifies a surface molecule with multi-functional activity. Its prognostic importance in B-cell chronic lymphocytic leukemia (B-CLL) is currently under investigation in view of the fact that two different groups have recently indicated that CD38 expression could be an independent prognostic marker in B-CLL. We analyzed the clinico-biological features of 61 immunologically typical (CD5+CD23+) B-CLL patients stratified according to the CD38 expression. Twenty-two (36%) patients expressed CD38 in more than 30% of CD19-positive cells and were considered as CD38-positive B-CLL. Atypical morphology (p 0.02), peripheral blood lymphocytosis (p 0.01) and diffuse histopathologic bone marrow pattern (p 0.003) were findings found to be closely associated with CD38 expression. On the other hand, A and B Binet stages (p 0.02) and interstitial bone marrow involvement (p 0.005) were more represented in the CD38-negative B-CLL group. Trisomy 12 was detected more frequently in the CD38-positive B-CLL group, while 13q14 deletions mainly occurred in CD38-negative group (p 0.005). Finally, median survival of CD38-positive B-CLL patients was 90 months, while it was not reached at 180 months in CD38-negative patients. Taken together, our data strongly suggest that the evaluation of CD38 expression may identify two groups patients with B-CLL greatly differing in their clinico-biological features.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalLeukemia and Lymphoma
Volume42
Issue number1-2
Publication statusPublished - 2001

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Bone Marrow
Lymphocytosis
Trisomy
Survival

Keywords

  • CD38
  • Chronic lymphocytic leukemia
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. / D'Arena, G.; Musto, P.; Cascavilla, N.; Dell'Olio, M.; Di Renzo, N.; Perla, G.; Savino, L.; Carotenuto, M.

In: Leukemia and Lymphoma, Vol. 42, No. 1-2, 2001, p. 109-114.

Research output: Contribution to journalArticle

D'Arena, G. ; Musto, P. ; Cascavilla, N. ; Dell'Olio, M. ; Di Renzo, N. ; Perla, G. ; Savino, L. ; Carotenuto, M. / CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2001 ; Vol. 42, No. 1-2. pp. 109-114.
@article{806176beb5264a7da099f0b44e53084a,
title = "CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia",
abstract = "CD38 identifies a surface molecule with multi-functional activity. Its prognostic importance in B-cell chronic lymphocytic leukemia (B-CLL) is currently under investigation in view of the fact that two different groups have recently indicated that CD38 expression could be an independent prognostic marker in B-CLL. We analyzed the clinico-biological features of 61 immunologically typical (CD5+CD23+) B-CLL patients stratified according to the CD38 expression. Twenty-two (36{\%}) patients expressed CD38 in more than 30{\%} of CD19-positive cells and were considered as CD38-positive B-CLL. Atypical morphology (p 0.02), peripheral blood lymphocytosis (p 0.01) and diffuse histopathologic bone marrow pattern (p 0.003) were findings found to be closely associated with CD38 expression. On the other hand, A and B Binet stages (p 0.02) and interstitial bone marrow involvement (p 0.005) were more represented in the CD38-negative B-CLL group. Trisomy 12 was detected more frequently in the CD38-positive B-CLL group, while 13q14 deletions mainly occurred in CD38-negative group (p 0.005). Finally, median survival of CD38-positive B-CLL patients was 90 months, while it was not reached at 180 months in CD38-negative patients. Taken together, our data strongly suggest that the evaluation of CD38 expression may identify two groups patients with B-CLL greatly differing in their clinico-biological features.",
keywords = "CD38, Chronic lymphocytic leukemia, Prognostic factors",
author = "G. D'Arena and P. Musto and N. Cascavilla and M. Dell'Olio and {Di Renzo}, N. and G. Perla and L. Savino and M. Carotenuto",
year = "2001",
language = "English",
volume = "42",
pages = "109--114",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "1-2",

}

TY - JOUR

T1 - CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia

AU - D'Arena, G.

AU - Musto, P.

AU - Cascavilla, N.

AU - Dell'Olio, M.

AU - Di Renzo, N.

AU - Perla, G.

AU - Savino, L.

AU - Carotenuto, M.

PY - 2001

Y1 - 2001

N2 - CD38 identifies a surface molecule with multi-functional activity. Its prognostic importance in B-cell chronic lymphocytic leukemia (B-CLL) is currently under investigation in view of the fact that two different groups have recently indicated that CD38 expression could be an independent prognostic marker in B-CLL. We analyzed the clinico-biological features of 61 immunologically typical (CD5+CD23+) B-CLL patients stratified according to the CD38 expression. Twenty-two (36%) patients expressed CD38 in more than 30% of CD19-positive cells and were considered as CD38-positive B-CLL. Atypical morphology (p 0.02), peripheral blood lymphocytosis (p 0.01) and diffuse histopathologic bone marrow pattern (p 0.003) were findings found to be closely associated with CD38 expression. On the other hand, A and B Binet stages (p 0.02) and interstitial bone marrow involvement (p 0.005) were more represented in the CD38-negative B-CLL group. Trisomy 12 was detected more frequently in the CD38-positive B-CLL group, while 13q14 deletions mainly occurred in CD38-negative group (p 0.005). Finally, median survival of CD38-positive B-CLL patients was 90 months, while it was not reached at 180 months in CD38-negative patients. Taken together, our data strongly suggest that the evaluation of CD38 expression may identify two groups patients with B-CLL greatly differing in their clinico-biological features.

AB - CD38 identifies a surface molecule with multi-functional activity. Its prognostic importance in B-cell chronic lymphocytic leukemia (B-CLL) is currently under investigation in view of the fact that two different groups have recently indicated that CD38 expression could be an independent prognostic marker in B-CLL. We analyzed the clinico-biological features of 61 immunologically typical (CD5+CD23+) B-CLL patients stratified according to the CD38 expression. Twenty-two (36%) patients expressed CD38 in more than 30% of CD19-positive cells and were considered as CD38-positive B-CLL. Atypical morphology (p 0.02), peripheral blood lymphocytosis (p 0.01) and diffuse histopathologic bone marrow pattern (p 0.003) were findings found to be closely associated with CD38 expression. On the other hand, A and B Binet stages (p 0.02) and interstitial bone marrow involvement (p 0.005) were more represented in the CD38-negative B-CLL group. Trisomy 12 was detected more frequently in the CD38-positive B-CLL group, while 13q14 deletions mainly occurred in CD38-negative group (p 0.005). Finally, median survival of CD38-positive B-CLL patients was 90 months, while it was not reached at 180 months in CD38-negative patients. Taken together, our data strongly suggest that the evaluation of CD38 expression may identify two groups patients with B-CLL greatly differing in their clinico-biological features.

KW - CD38

KW - Chronic lymphocytic leukemia

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0034917928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034917928&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 109

EP - 114

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -